SG Americas Securities LLC Sells 13,127 Shares of Celcuity, Inc. $CELC

SG Americas Securities LLC reduced its position in Celcuity, Inc. (NASDAQ:CELC) by 71.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 5,300 shares of the company’s stock after selling 13,127 shares during the period. SG Americas Securities LLC’s holdings in Celcuity were worth $605,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EverSource Wealth Advisors LLC increased its position in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Celcuity in the fourth quarter valued at approximately $42,000. Ogorek Anthony Joseph NY ADV lifted its position in shares of Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after buying an additional 109 shares during the last quarter. US Bancorp DE lifted its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the last quarter. Finally, NBC Securities Inc. bought a new position in shares of Celcuity during the 4th quarter worth approximately $99,000. Institutional investors own 63.33% of the company’s stock.

Insider Activity

In other news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by insiders.

Celcuity Stock Up 6.6%

CELC opened at $115.72 on Wednesday. Celcuity, Inc. has a fifty-two week low of $13.31 and a fifty-two week high of $151.02. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The company has a market capitalization of $5.64 billion, a P/E ratio of -29.67 and a beta of 0.16. The stock has a fifty day moving average of $112.49 and a 200-day moving average of $110.86.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, equities analysts expect that Celcuity, Inc. will post -3.69 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on CELC. Stifel Nicolaus set a $150.00 target price on Celcuity in a report on Monday, May 4th. Wells Fargo & Company cut their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Guggenheim reissued a “buy” rating on shares of Celcuity in a research report on Wednesday, June 3rd. Finally, HC Wainwright cut their target price on shares of Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $152.09.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.